Skip to main content
SpringerLink
Log in

Autoimmune Cytopenia in Chronic Lymphocytic Leukemia

  • Chapter
  • First Online:
Chronic Lymphocytic Leukemia

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 924 Accesses

Abstract

The presence of anemia and/or thrombocytopenia is not infrequent in CLL and defines advanced, poor prognosis disease. Given their multiple possible causes, patients with CLL presenting cytopenia require a careful evaluation and an individualized management. The association of CLL with cytopenias of immune origin is based on experts’ consensus, and its impact on patients’ outcome remains controversial. It is widely accepted that treatment should be the same as in idiopathic immune cytopenias (i.e., corticosteroids and/or anti-CD20 monoclonal antibodies) with failure to respond to conventional treatment being an indication for anti-CLL therapy. Interestingly, analysis of retrospective series suggests that novel oral targeted therapies (i.e., ibrutinib) might be effective to treat autoimmune cytopenias complicating CLL. Prospective studies are needed to clarify the role of signal inhibitors in the management of autoimmune cytopenias in CLL.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Phillips JA, Mehta K, Fernandez C, Raveché ES. The NZB mouse as a model for chronic lymphocytic leukemia. Cancer Res. 1992;52(2):437–43.

    CAS  PubMed  Google Scholar 

  2. Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood. 1993;81(10):2475–87.

    CAS  PubMed  Google Scholar 

  3. Ghia P, Scielzo C, Frenquelli M, Muzio M, Caligaris-Cappio F. From normal to clonal B cells: chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmun Rev. 2007;7:127–31.

    Article  CAS  PubMed  Google Scholar 

  4. Myhrinder AL, Hellqvist E, Sidorova E, Söderberg A, Baxendale H, Dahle C, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 2008;111(7):3838–48.

    Article  CAS  Google Scholar 

  5. Ternynck T, Dighiero G, Follezou J, Binet JL. Comparison of normal and CLL lymphocyte surface Ig determinants using peroxidase-labeled antibodies. I. Detection and quantitation of light chain determinants. Blood. 1974;43(6):789–95.

    CAS  PubMed  Google Scholar 

  6. Chu CC, Catera R, Zhang L, Didier S, Agagnina BM, Damle RN, et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood. 2010;115(19):3907–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol. 2008;4(9):491–8. https://doi.org/10.1038/ncprheum0895.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Maura F, Visco C, Falisi E, Reda G, Fabris S, Agnelli L, et al. B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. Am J Hematol. 2013;88(1):32–6.

    Article  CAS  PubMed  Google Scholar 

  9. Quinquenel A, Al Nawakil C, Baran-Marszak F, Eclache V, Letestu R, Khalloufi M, et al. Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients. Am J Hematol. 2015;90(1):E5–8.

    Article  PubMed  Google Scholar 

  10. Carli G, Visco C, Falisi E, Perbellini O, Novella E, Giaretta I, et al. Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome. Ann Hematol. 2016;95(6):863–70.

    Article  CAS  PubMed  Google Scholar 

  11. Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood. 2005;105(5):2007–15.

    Article  CAS  PubMed  Google Scholar 

  12. Galletti J, Cañones C, Morande P, Borge M, Oppezzo P, Geffner J, et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune hemolytic anemia. J Immunol. 2008;181(5):3674–83.

    Article  CAS  PubMed  Google Scholar 

  13. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):230–9.

    Article  CAS  PubMed  Google Scholar 

  14. von Bergwelt-Baildon M, Maecker B, Schultze J, Gribben JG. CD40 activation: potential for specific immunotherapy in B-CLL. Ann Oncol. 2004;15:853–7.

    Article  Google Scholar 

  15. Görgün G, Holderried TAW, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115(7):1797–805. http://www.ncbi.nlm.nih.gov/pubmed/15965501. http://www.jci.org/articles/view/24176/pdf. http://www.ncbi.nlm.nih.gov/pubmed/15965501?dopt=Abstract. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1150284&blobtype=pdf. http://www.pubmedce.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood. 2000;95(9):2786–92. http://www.bloodjournal.org/content/95/9/2786.abstract.

    CAS  PubMed  Google Scholar 

  17. Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, et al. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood. 1998;91(11):4273–81.

    CAS  PubMed  Google Scholar 

  18. Itälä M, Vainio O, Remes K. Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia. Eur J Haematol. 1996;57(1):46–53.

    Article  PubMed  Google Scholar 

  19. Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia. 2008;22(5):998–1006. http://www.ncbi.nlm.nih.gov/pubmed/18288133.

    Article  CAS  PubMed  Google Scholar 

  20. Barcellini W, Imperiali FG, Zaninoni A, Reda G, Consonni D, Fattizzo B, et al. Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression. Leuk Lymphoma. 2014;55(8):1768–73. https://doi.org/10.3109/10428194.2013.856426.

    Article  CAS  PubMed  Google Scholar 

  21. Lad DP, Varma S, Varma N, Sachdeva MUS, Bose P, Malhotra P. Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias. Leuk Lymphoma. 2015;56(8):2424–8. http://www.ncbi.nlm.nih.gov/pubmed/25393804.

    Article  CAS  PubMed  Google Scholar 

  22. Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, et al. T cells from CLLpatients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Riches JC, Ramsay AG, Gribben JG. T-cell function in chronic lymphocytic leukaemia. Semin Cancer Biol. 2010;20(6):431–8. [cited 2017 Dec 18]. http://www.ncbi.nlm.nih.gov/pubmed/20920582.

    Article  CAS  PubMed  Google Scholar 

  24. Ramsay AG, Gribben JG. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. Haematologica. 2009;94(9):1198–202. [cited 2017 Dec 18]. http://www.ncbi.nlm.nih.gov/pubmed/19734414.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Sampalo A, Brieva JA. Humoral immunodeficiency in chronic lymphocytic leukemia: role of CD95/CD95L in tumoral damage and escape. Leuk Lymphoma. 2002;43(4):881–4.

    Article  CAS  PubMed  Google Scholar 

  26. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793–801.

    Article  CAS  PubMed  Google Scholar 

  27. Niederer F, Trenkmann M, Ospelt C, Karouzakis E, Neidhart M, Stanczyk J, et al. Down-regulation of microRNA-34a* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. Arthritis Rheum. 2012;64(6):1771–9.

    Article  CAS  PubMed  Google Scholar 

  28. Shen N, Liang D, Tang Y, de Vries N, Tak P-P. MicroRNAs—novel regulators of systemic lupus erythematosus pathogenesis. Nat Rev Rheumatol. 2012;8(12):701–9. https://doi.org/10.1038/nrrheum.2012.142.

    Article  CAS  PubMed  Google Scholar 

  29. Ferrer G, Navarro A, Hodgson K, Aymerich M, Pereira A, Baumann T, et al. MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia. Leuk Lymphoma. 2013;54(9):2016–22. https://doi.org/10.3109/10428194.2012.763123.

    Article  CAS  PubMed  Google Scholar 

  30. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol. 1986;39(7):713–6. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=500029&tool=pmcentrez&rendertype=abstract.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Barcellini W, Capalbo S, Agostinelli RM, Mauro FR, Ambrosetti A, Calori R, et al. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica. 2006;91(12):1689–92.

    PubMed  Google Scholar 

  32. Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008;111(4):1820–6.

    Article  CAS  PubMed  Google Scholar 

  33. Zent CS, Ding W, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol. 2008;141(5):615–21.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA, et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma. 2009;50(8):1261–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Moreno C, Hodgson K, Ferrer G, Elena M, Filella X, Pereira A, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood. 2010;116(23):4771–6.

    Article  CAS  PubMed  Google Scholar 

  36. Zanotti R, Frattini F, Ghia P, Visco C, Zamò A, Perbellini O, et al. ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients. Am J Hematol. 2010;85(7):494–8.

    Article  CAS  PubMed  Google Scholar 

  37. Visco C, Cortelezzi A, Moretta F, Falisi E, Maura F, Finotto S, et al. Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? Leuk Lymphoma. 2014;55(6):1261–5. https://doi.org/10.3109/10428194.2013.834054.

    Article  CAS  PubMed  Google Scholar 

  38. Landgren O, Gridley G, Check D, Caporaso NE, Morris Brown L. Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol. 2007;139(5):791–8.

    Article  PubMed  Google Scholar 

  39. Mittal S, Blaylock MG, Culligan DJ, Barker RN, Vickers MA. A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura. Haematologica. 2008;93(1):151–2.

    Article  PubMed  Google Scholar 

  40. Kyasa MJ, Parrish RS, Schichman SA, Zent CS. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2003;74(1):1–8.

    Article  PubMed  Google Scholar 

  41. Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood. 2017;129:2971–9.

    Article  CAS  PubMed  Google Scholar 

  42. Dameshek W. Chronic lymphocytic leukemia—an accumulative disease of immunolgically incompetent lymphocytes. Blood. 1967;29(4):566–84. http://www.bloodjournal.org/content/29/4/566.abstract.

    Google Scholar 

  43. Lewis FB, Schwartz RS, Dameshek W. X-radiation and alkylating agents as possible ‘trigger’ mechanisms in the autoimmune complications of malignant lymphophroliferative disease. Clin Exp Immunol. 1966;1(1):3–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Bastion Y, Coiffier B, Dumontet C, Espinouse D, Bryon PA. Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol. 1992;3(2):171–2.

    Article  CAS  PubMed  Google Scholar 

  45. Tosti S, Caruso R, D’Adamo F, Picardi A, Ege MA, Girelli G, et al. Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment. Ann Hematol. 1992;65:238–9.

    Article  CAS  PubMed  Google Scholar 

  46. Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol. 1995;91(2):341–4.

    Article  CAS  PubMed  Google Scholar 

  47. Borthakur G, O’Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab - incidence and predictors. Br J Haematol. 2007;136(6):800–5.

    Article  CAS  PubMed  Google Scholar 

  48. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74.

    Article  CAS  PubMed  Google Scholar 

  49. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2008;2008(1):450–6. http://asheducationbook.hematologylibrary.org/content/2008/1/450.abstract.

    Article  Google Scholar 

  50. Zent CS, Shanafelt T. Management of autoimmune cytopenia complicating chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:863–4.

    Article  PubMed  Google Scholar 

  51. Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114–21. https://doi.org/10.1182/blood-2013-02-474437. [cited 2017 Dec 18].

    Article  CAS  PubMed  Google Scholar 

  52. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219–34. http://www.ncbi.nlm.nih.gov/pubmed/1139039.

    CAS  PubMed  Google Scholar 

  53. Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol. 2010;23(1):47–59. [cited 2017 Dec 18]. http://www.ncbi.nlm.nih.gov/pubmed/20620970.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood. 2002;99(3):1092–4. [cited 2017 Dec 18]. http://www.ncbi.nlm.nih.gov/pubmed/11807020.

    Article  CAS  PubMed  Google Scholar 

  55. Viny AD, Lichtin A, Pohlman B, Loughran T, Maciejewski J. Chronic B-cell dyscrasias are an important clinical feature of T-LGL leukemia. Leuk Lymphoma. 2008;49(5):932–8. [cited 2017 Dec 18]. http://www.ncbi.nlm.nih.gov/pubmed/18452068.

    Article  CAS  PubMed  Google Scholar 

  56. Shvidel L, Tadmor T, Braester A, Bairey O, Rahimi-Levene N, Herishanu Y, et al. Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): a retrospective comparative study of 213 patients from a national CLL database of 1518 cases. Ann Hematol. 2013;92(5):661–7.

    Article  PubMed  Google Scholar 

  57. Alzaki AA, Gerrie AS, Gillan TL, Huang S, Ahmed M, Toze CL, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: effect on outcome and survival, a population based analysis in British Columbia, Canada. Blood. 2014;124(21):1945. [cited 2017 Dec 18]. http://www.bloodjournal.org/content/124/21/1945?sso-checked=true.

    Google Scholar 

  58. Ricci F, Tedeschi A, Vismara E, Colombo C, Veronese S, Nichelatti M, et al. Should a positive direct antiglobulin test be considered a prognostic predictor in chronic lymphocytic leukemia? Clin Lymphoma Myeloma Leuk. 2013;13(4):441–6.

    Article  PubMed  Google Scholar 

  59. Ruzickova S, Pruss A, Odendahl M, Wolbart K, Burmester GR, Scholze J, et al. Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light-chain diversity in V H4-34 expressing single leukemic B cells. Blood. 2002;100(9):3419–22.

    Article  CAS  PubMed  Google Scholar 

  60. Zaja F, Vianelli N, Sperotto A, Patriarca F, Tani M, Marin L, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma. 2003;44(11):1951–5.

    Article  CAS  PubMed  Google Scholar 

  61. D’Arena G, Laurenti L, Capalbo S, D’Arco AM, De Filippi R, Marcacci G, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol. 2006;81(8):598–602. http://www.ncbi.nlm.nih.gov/pubmed/16823816.

    Article  PubMed  Google Scholar 

  62. Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr Opin Mol Ther. 2008;10(3):294–309. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L351799281. http://library.brown.edu/easyarticle?sid=EMBASE&issn=14648431&id=doi:&atitle=Ofatumumab%2C+a+human+monoclonal+antibody+for+lymphoid+malignancies+and+autoimmune+disorder.

    CAS  PubMed  Google Scholar 

  63. Nader K, Patel M, Ferber A. Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2013;13:511–3.

    Article  PubMed  Google Scholar 

  64. Bowen DA, Call TG, Shanafelt TD, Kay NE, Schwager SM, Reinalda MS, et al. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma. 2010;51(4):620–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Gupta N, Kavuru S, Patel D, Janson D, Driscoll N, Ahmed S, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leuk Off J Leuk Soc Am Leuk Res Fund UK. 2002;16(10):2092–5. https://doi.org/10.1038/sj.leu.2402676.

    Article  CAS  Google Scholar 

  66. Kaufman M, Limaye SA, Driscoll N, Johnson C, Caramanica A, Lebowicz Y, et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(6):892–9.

    Article  CAS  PubMed  Google Scholar 

  67. Michallet A-S, Rossignol J, Cazin B, Ysebaert L. Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leuk Lymphoma. 2011;52(7):1401–3. https://doi.org/10.3109/10428194.2011.591005.

    Article  CAS  PubMed  Google Scholar 

  68. Quinquenel A, Willekens C, Dupuis J, Royer B, Ysebaert L, De Guibert S, et al. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS). Am J Hematol. 2015;90(3):204–7.

    Article  CAS  PubMed  Google Scholar 

  69. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014;99:1547–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Dierickx D, Verhoef G, Delannoy A. Rituximab in patients with refractory autoimmune hemolytic anemia. Ann Hematol. 2011;90:985–6.

    Article  PubMed  Google Scholar 

  71. Saha M, Ray S, Kundu S, Chakrabarti P. Pure red cell aplasia following autoimmune hemolytic anemia: an enigma. J Postgrad Med. 2013;59(1):51–3. http://www.jpgmonline.com/text.asp?2013/59/1/51/109495. http://www.ncbi.nlm.nih.gov/pubmed/23525059.

    Article  CAS  PubMed  Google Scholar 

  72. Sekiguchi Y, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, et al. A case of recurrent autoimmune hemolytic anemia during remission associated with acute pure red cell aplasia and hemophagocytic syndrome due to human parvovirus B19 infection successfully treated by steroid pulse therapy with a review of the literature. Int J Clin Exp Pathol. 2014;7(5):2624–35.

    PubMed  PubMed Central  Google Scholar 

  73. Adachi M. Simultaneous occurrence of autoimmune hemolytic anemia and pure red cell aplasia. Rinsho Ketsueki. 2016;57(12):2512–6.

    PubMed  Google Scholar 

  74. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Rogers KA, Ruppert AS, Bingman A, Andritsos LA, Awan FT, Blum KA, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2016;30:346. https://doi.org/10.1038/leu.2015.273.

    Article  CAS  PubMed  Google Scholar 

  76. Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2016;101:e254–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Montillo M, O’Brien S, Tedeschi A, Byrd JC, Dearden C, Gill D, et al. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. Blood Cancer J. 2017;7(2):e524.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37. https://doi.org/10.1056/NEJMoa1509388. http://www.ncbi.nlm.nih.gov/pubmed/26639149.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–32. https://doi.org/10.1056/NEJMoa1509981.

    Article  CAS  PubMed  Google Scholar 

  80. Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–78.

    Article  CAS  PubMed  Google Scholar 

  81. Manda S, Dunbar N, Marx-Wood CR, Danilov AV. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. Br J Haematol. 2015;170:734–6.

    Article  PubMed  Google Scholar 

  82. Molica S, Levato L, Mirabelli R. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature. Leuk Lymphoma. 2016;57(3):735–7.

    Article  PubMed  Google Scholar 

  83. Rider TG, Grace RJ, Newman JA. Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia. Br J Haematol. 2016;173:326–7.

    Article  PubMed  Google Scholar 

  84. Winqvist M, Asklid A, Andersson PO, Karlsson K, Karlsson C, Lauri B, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica. 2016;101(12):1573–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. UK CLL Forum. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016;101(12):1563–72.

    Article  PubMed Central  Google Scholar 

  86. Michallet AS, Campidelli A, Lequeu H, Dilhuydy MS, Tournilhac O, Fornecker LM, et al. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: a real-world experience of 71 patients treated in France: a study from the French Innovative Leukemia Organization (FILO) group. Am J Hematol. 2017;92:E105–7.

    Article  PubMed  Google Scholar 

  87. Iskierka-Jażdżewska E, Hus M, Giannopoulos K, Mądro E, Hołojda J, Piotrowska M, et al. Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG). Leuk Lymphoma. 2017;58:2485–8.

    Article  PubMed  Google Scholar 

  88. Hampel PJ, Larson MC, Kabat B, Call TG, Ding W, Kenderian SS, et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib in routine clinical practice at an academic medical center. Blood. 2017;130(Suppl 1):3023. [cited 2017 Dec 18]. http://www.bloodjournal.org/content/130/Suppl_1/3023.

    Google Scholar 

  89. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Robak T, Robak E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Investig Drugs. 2012;21(7):921–47. https://doi.org/10.1517/13543784.2012.685650.

    Article  CAS  PubMed  Google Scholar 

  91. Fagiolo E, Toriani-Terenzi C. Th1 and Th2 cytokine modulation by IL-10/IL-12 imbalance in autoimmune haemolytic anaemia (AIHA). Autoimmunity. 2002;35(1):39–44.

    Article  CAS  PubMed  Google Scholar 

  92. Cavazzini F, Lista E, Quaglia FM, Formigaro L, Cavallari M, Martinelli S, et al. Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. Leuk Lymphoma. 2016;57(11):2685–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Hospital Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

    Carol Moreno, Carolina Cuellar & Eva Puy Vicente

Authors
  1. Carol Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carolina Cuellar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eva Puy Vicente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carol Moreno .

Editor information

Editors and Affiliations

  1. Department I of Internal Medicine, University of Cologne, Cologne, Nordrhein-Westfalen, Germany

    Michael Hallek

  2. Department I of Internal Medicine, University of Cologne, Cologne, Nordrhein-Westfalen, Germany

    Barbara Eichhorst

  3. Division of Molecular Pathology, The Institute of Cancer Research, London, UK

    Daniel Catovsky

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Moreno, C., Cuellar, C., Vicente, E.P. (2019). Autoimmune Cytopenia in Chronic Lymphocytic Leukemia. In: Hallek, M., Eichhorst, B., Catovsky, D. (eds) Chronic Lymphocytic Leukemia. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-11392-6_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11392-6_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-11391-9

  • Online ISBN: 978-3-030-11392-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation